Month: May 2020

Port Delivery System with ranibizumab (PDS) is a permanent refillable eye implant that continuously delivers ranibizumab over a period of months, potentially reducing the treatment burden associated with frequent eye injectionsRefilled every six months, PDS demonstrated non-inferior and equivalent efficacy compared to the standard of care – monthly ranibizumab eye injections – for people with neovascular age-related macular degenerationData from the Archway study will be presented at an upcoming medical meeting and submitted to health authorities around the worldBasel, 27 May 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the phase III Archway study, evaluating Port Delivery System with ranibizumab (PDS) in people living with neovascular or “wet” age-related macular degeneration (nAMD). PDS...

New MONALEESA-7 (M7) and MONALEESA-3 (M3) subgroup analysis to be presented during ASCO20 Virtual Scientific Program Subgroup analysis shows Kisqali plus endocrine therapy extended life compared to endocrine therapy for patients with liver metastases – showing ~47% and 37% reduction in the risk of death in M7 and M3, respectively1 Visceral metastases, especially liver or brain metastases, generally signify a poor prognosis and more aggressive disease for patients2,3 Results add to body of evidence, reinforce Kisqali consistent overall survival benefit regardless of type of metastases, endocrine partner or menopausal statusBasel, May 27, 2020 — Novartis today announced a new exploratory subgroup analysis of the Phase III MONALEESA-3 and MONALEESA-7 trials, to be presented during the ASCO20 Virtual Scientific Program, reinforcing the overall...

Rapid and profound depletion of B-cells contributed to a halt in disease activity in RMS patients1 A post hoc analysis showed 47.0% and 87.8% of patients treated with ofatumumab achieved no evidence of disease activity (NEDA-3) within the first (0–12 months) and second year (12–24 months) of treatment, respectively1 Regulatory action for ofatumumab in RMS in the US is expected in June 2020 If approved, ofatumumab has the potential to become a first-choice treatment for RMS patients and the first B-cell therapy that can be self-administered at home using an autoinjector penBasel, May 27, 2020 — Novartis announced today that new ofatumumab data from the Phase III ASCLEPIOS trials and the Phase II APLIOS trial were presented virtually at the 6th Congress of the European Academy of Neurology (EAN). The data continue to demonstrate ofatumumab...

Oslo, 27 May 2020 – DNO ASA, the Norwegian oil and gas operator, today provided production and spend guidance for the balance of the year ahead of its Annual General Meeting this afternoon. The Company reported that it has implemented the target 35 percent reductions across all spend categories to shrink its 2020 budget by USD 350 million to USD 640 million in response to turbulence and uncertainty in global oil and financial markets triggered by the coronavirus pandemic. While strengthening its balance sheet, cutbacks in spend will throttle back 2020 Company Working Interest (CWI) production to a projected 88,000 barrels of oil equivalent per day (boepd), of which the Kurdistan region of Iraq will contribute 71,000 barrels of oil per day (bopd) and the North Sea 17,000 boepd. DNO’s CWI production averaged 104,800 boepd last year.In Kurdistan,...

SAN FRANCISCO, May 26, 2020 (GLOBE NEWSWIRE) — 1Life Healthcare, Inc. (One Medical) (Nasdaq: ONEM) today announced the pricing of $275 million aggregate principal amount of 3.00% convertible senior notes due 2025 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The size of the offering was increased from the previously announced $250 million. One Medical also granted the initial purchasers of the notes a 13-day option to purchase up to an additional $41.25 million principal amount of notes on the same terms and conditions. The sale of the notes is expected to close on May 29, 2020, subject to customary closing conditions.The notes will be general unsecured obligations of One Medical and bear interest at a rate of 3.00% per annum, payable...

CHANDLER, Arizona, May 27, 2020 (GLOBE NEWSWIRE) — Microchip Technology Incorporated (NASDAQ: MCHP) (“Microchip,” “we” or “our”) announced today the pricing of $1.0 billion in aggregate principal amount of senior secured notes due September 1, 2023 (the “Senior Secured Notes”) and $1.2 billion in aggregate principal amount of senior notes due September 1, 2025 (the “Senior Notes” and, together with the Senior Secured Notes, the “Notes”).  The Senior Secured Notes will bear interest at an annual rate of 2.670 percent and the Senior Notes will bear interest at annual rate of 4.250 percent.  The offering of the Notes is expected to close on May 29, 2020, subject to customary closing conditions.Microchip intends to use approximately $615 million of the net proceeds from the offering of the Senior Secured Notes to repay in full all amounts...

ANN ARBOR, Mich., May 26, 2020 (GLOBE NEWSWIRE) — Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced the pricing of a public offering of 133,333,333 common shares (or common share equivalents) of the Company, together with warrants to purchase up to 133,333,333 common shares, at a combined public offering price of $0.15 per share and accompanying warrant. Each common share (or common share equivalent) is being sold in the offering together with one two-year warrant to purchase one common share at an exercise price of $0.15 per common share. There is no established public trading market for the warrants, and Zomedica does not expect a market to develop.H.C. Wainwright & Co. is acting as exclusive placement agent for the offering.The gross proceeds...

MARKHAM, Ontario, May 26, 2020 (GLOBE NEWSWIRE) — Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today issued the following statement with respect to a report by the Canadian Forces.Today, we received a copy of a report by the Canadian Forces listing observations from Altamont Care Community (“Altamont”), where it has been working alongside our team since April 27, 2020. We continue to be deeply saddened by the impact the pandemic is having on long-term care homes. Our commitment to our residents, their families and our team members is to work with government to make sure the concerns identified by the Canadian Forces are addressed.With the support of the Canadian Forces, Altamont has continuously evaluated and implemented additional measures, processes, and protocols in line with provincial and public health directives...

DELTA, British Columbia, May 26, 2020 (GLOBE NEWSWIRE) — WestBond Enterprises Corporation (TSX-V: WBE) is pleased to announce that its wholly owned subsidiary, WestBond Industries Inc. has been issued a DIN (Drug Identification Number) by Health Canada to produce wet disinfectant wipes.  These surface wipes will be marketed under WestBond’s trademark VIROBAN PLUS.The company already produces dry patient wipes for the health care industry and recognized the need for adding wet wipes to its product line.  The manufacturing equipment was purchased over the last year and is now being tested after all the regulatory requirements were satisfied regarding the disinfectant formulation and product claims. Production and sales are planned for late July of this year.  The company expects to significantly increase sales and profits due to the...